Top

07-04-2024 | Hepatocellular Carcinoma | Original Article

Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes

Authors: Yi-Hao Yen, Fang-Ying Kuo, Hock-Liew Eng, Yueh-Wei Liu, Chee-Chien Yong, Chih-Chi Wang, Wei-Feng Li, Chih-Yun Lin

Published in: Updates in Surgery

Abstract

Numerous studies have compared outcomes of liver resection (LR) of patients with non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) to those of patients with non-NAFLD-related HCC. However, results have been inconsistent. We aim to clarify this issue. We enrolled 801 patients with hepatitis B virus (HBV)-related HCC, 433 patients with hepatitis C virus (HCV)-related HCC, and 128 patients with NAFLD-related HCC undergoing LR. Overall survival (OS) and disease-free survival (DFS) of patients with different etiologies of chronic liver disease was compared using the Kaplan–Meier estimator and log-rank test after propensity score matching (PSM). After PSM, 83 patients remained in each group. The groups did not differ significantly in age, sex, the proportion of patients with pathological American Joint Committee on Cancer stage 1, tumor size > 50 mm, receipt of major resection, alpha-fetoprotein (AFP) ≥ 20 ng/ml, presence of cirrhosis, model for end-stage liver disease (MELD) score, and American Society of Anesthesiologists (ASA) classification. The five-year OS of patients with HBV-, HCV-, and NAFLD-related HCC was 78%, 75%, and 78%, respectively (p = 0.789). The five-year DFS of the HBV, HCV, and NAFLD groups was 60%, 45%, and 54%, respectively (p = 0.159). Perioperative morbidity was noted in 17 (20.5%) in the HBV group, 22 (26.5%) in the HCV group, and 15 (18.1%) in the NAFLD group (p = 0.398). The five-year OS, DFS, and perioperative morbidity of patients undergoing LR for NAFLD-related HCC and those for viral hepatitis-related HCC was similar.

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589–604. https://doi.org/10.1038/s41575-019-0186-yCrossRefPubMedPubMedCentral

Yen YH, Kee KM, Li WF, Liu YW, Wang CC, Hu TH et al (2023) Stationary trend in elevated serum alpha-fetoprotein level in hepatocellular carcinoma patients. Cancers (Basel) 15:1222. https://doi.org/10.3390/cancers15041222CrossRefPubMedPubMedCentral

Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M et al (2015) Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62:1723–1730. https://doi.org/10.1002/hep.28123CrossRefPubMed

Karim MA, Singal AG, Kum HC, Lee YT, Park S, Rich NE et al (2023) Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol 21:670-680.e18. https://doi.org/10.1016/j.cgh.2022.03.010CrossRefPubMed

Viganò L, Conci S, Cescon M, Fava C, Capelli P, D’Errico A et al (2015) Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol 63:93–101. https://doi.org/10.1016/j.jhep.2015.01.024CrossRefPubMed

Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V (2017) Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 46:856–863. https://doi.org/10.1111/apt.14261CrossRefPubMed

Koh YX, Tan HJ, Liew YX, Syn N, Teo JY, Lee SY et al (2019) Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Am Coll Surg 229:467-478.e1. https://doi.org/10.1016/j.jamcollsurg.2019.07.012CrossRefPubMed

Pal Chaudhary S, Reyes S, Chase ML, Govindan A, Zhao L, Luther J et al (2023) Resection of NAFLD/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies. Oncologist 28:341–350. https://doi.org/10.1093/oncolo/oyac251CrossRefPubMedPubMedCentral

Conci S, Cipriani F, Donadon M, Marchitelli I, Ardito F, Famularo S, et al, He.RC.O.Le.S Group (2022) Hepatectomy for metabolic associated fatty liver disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol 48:103–112. https://doi.org/10.1016/j.ejso.2021.07.015.

10.

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V et al (2020) Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 1:935-944.e3. https://doi.org/10.1016/j.cgh.2019.08.011CrossRef

11.

Yip TC, Lee HW, Chan WK, Wong GL, Wong VW (2022) Asian perspective on NAFLD-associated HCC. J Hepatol 76:726–734. https://doi.org/10.1016/j.jhep.2021.09.024CrossRefPubMed

12.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77:1797–1835. https://doi.org/10.1097/HEP.0000000000000323CrossRefPubMed

13.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The Eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388CrossRefPubMed

14.

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE et al (2010) Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51:585–594. https://doi.org/10.1002/hep.23315CrossRefPubMed

15.

Bryer J (2017) TriMatch: propensity score matching of non-binary treatments. Available online at: https://cran.r-project.org/web/packages/TriMatch/

16.

Andrade C (2020) Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry 81:20f13681. https://doi.org/10.4088/JCP.20f13681CrossRefPubMed

17.

Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864–871. https://doi.org/10.1053/he.2000.5852CrossRefPubMed

18.

Doyle DJ, Hendrix JM, Garmon EH (2024) American society of anesthesiologists classification. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, 17 Aug 2023

19.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.aeCrossRefPubMedPubMedCentral

20.

Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158:1999–2014. https://doi.org/10.1053/j.gastro.2019.11.312.e1CrossRefPubMed

21.

Caldwell SH, Crespo DM (2004) The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40:578–584. https://doi.org/10.1016/j.jhep.2004.02.013CrossRefPubMed

22.

Browning JD, Kumar KS, Saboorian MH, Thiele DL (2004) Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99:292–298. https://doi.org/10.1016/j.jhep.2004.02.013CrossRefPubMed

23.

Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH et al (2021) Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis 224:294–302. https://doi.org/10.1093/infdis/jiaa739CrossRefPubMed

24.

Shen HM, Ong CN (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 366:23–44. https://doi.org/10.1016/s0165-1110(96)90005-6CrossRefPubMed

25.

Ng AWT, Poon SL, Huang MN, Lim JQ, Boot A, Yu W et al (2017) Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 9:eaan6446. https://doi.org/10.1126/scitranslmed.aan6446CrossRefPubMed

26.

Wild CP, Miller JD, Groopman JD (2015) Mycotoxin control in low- and middle-income countries. International Agency for Research on Cancer, Lyon

27.

Gouas D, Shi H, Hainaut P (2009) The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 286:29–37. https://doi.org/10.1016/j.canlet.2009.02.057CrossRefPubMed

Title: Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
Authors: Yi-Hao Yen
Fang-Ying Kuo
Hock-Liew Eng
Yueh-Wei Liu
Chee-Chien Yong
Chih-Chi Wang
Wei-Feng Li
Chih-Yun Lin
Publication date: 07-04-2024
Publisher: Springer International Publishing
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Liver Resection
Liver Resection
Hepatitis B
Hepatitis C
Fatty Liver
Hepatitis
Published in: Updates in Surgery
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-024-01833-3

At a glance: The STEP trials

Springer Medicine

Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content